PET/MR Imaging in Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this project is to investigate if PET/MR imaging improves the accuracy in visualization and characterization of lung cancer disease, compared to PET/CT.

Detailed Description
-----------------
Lung cancer is the most frequent cancer type and the leading cause of cancer-related death worldwide. Positron emission tomography (PET) coupled with computed tomography (CT) is the standard of care for visualization and staging of lung cancer. Recent clinical introduction of hybrid PET and magnetic resonance (MR) imaging systems has shown potential to improve tumor imaging beyond the limits of PET/CT. However, knowledge about the clinical impact of this new hybrid modality is still limited. This project aims to investigate how PET/MR may improve the diagnosis and treatment of lung cancer disease, compared to PET/CT: PET/MR may allow early detection of brain and liver metastases, which strongly affects treatment outcome and survival; predictive models based on machine learning may combine image derived biomarkers from PET/MR, histology and health record data, to automatically visualize and characterize the tumor, facilitating computer aided diagnosis and personalized radiotherapy treatment.

Official Title
-----------------
Advancing Diagnosis and Treatment for Lung Cancer Patients Using Hybrid PET/MR Imaging and Novel Visualization Tools

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: PET/MR
* Diagnostic Test: PET/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Referred to clinical PET/CT examination for investigation of lung disease. Exclusion Criteria: Blood glucose level >8.3 mmol/l MR incompatible objects, e.g. metal implants, inside the body Intolerance to gadolinium-based contrast agents, e.g. severe renal disease (GFR<30). Unable to give written consent.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Nuclear medicine imaging<br>Patients undergo nuclear medicine imaging with PET/MR and PET/CT. | Diagnostic Test: PET/MR<br>* The included patients are imaged with PET/MR as part of the research protocol.<br>Diagnostic Test: PET/CT<br>* The included patients are imaged with PET/CT as part of normal clinical routine.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of PET/MR vs. clinical routine PET/CT | Sensitivity and specificity of PET/MR scans will be compared with in clinical routine PET/CT examinations for lung cancer disease feature prediction. | 1-2 weeks after the initial inclusion. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prediction of treatment response and progression-free survival | We will investigate which PET/MR or PET/CT features are best suited as an imaging biomarker for treatment response evaluation and for progression-free survival 1 year after inclusion. | 1 year after inclusion. | 
| Prediction of treatment response and progression-free survival | We will investigate which PET/MR or PET/CT features are best suited as an imaging biomarker for treatment response evaluation and for progression-free survival 2 years after inclusion. | 2 years after inclusion. | 
| Prediction of treatment response and progression-free survival | We will investigate which PET/MR or PET/CT features are best suited as an imaging biomarker for treatment response evaluation and for progression-free survival 5 years after inclusion. | 5 years after inclusion. |